Prototyping and Validation of Intervertebral Disc Bioreactors with Complex Loading Capacities

具有复杂负载能力的椎间盘生物反应器的原型设计和验证

• 批准号: 538388-2019
• 负责人: Li, Jianyu
• 金额: $ 1.82万
• 依托单位: McGill University
• 依托单位国家: 加拿大
• 项目类别: Engage Grants Program
• 财政年份: 2019
• 资助国家: 加拿大
• 起止时间: 2019-01-01 至 2020-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=681072
• 关键词: Prototyping; Validation; Intervertebral; Disc; Bioreactors

Low back pain (LBP) is tiredness, discomfort or pain in the low back, which leads to the medical expenditure of $12 billion annually in Canada. Clinical evidence has linked LBP with intervertebral disc (IVD) degeneration that often requires surgical intervention due to the lack of healing capacity of native IVD. There are a variety of implantable biomaterials under development for IVD repair. However, the development has been long bottlenecked by the lack of IVD bioreactors capable of reproducing the in vivo conditions in a laboratory setting. This project is focused on design, fabrication, and validation of a novel bioreactor for IVD studies. Such a device is designed to combine the capacity of compression, bending and torsion loading simultaneously, while is fully compatible with whole organ culture ex vivo. This project would directly address a critical need of a Canadian company for the development and validation of hydrogel implants for IVD repair. The device can enable high-throughput safety and efficacy evaluation of IVD implants, and mitigate the need of lengthy and expensive animal experiments. This project will address the need of the company, set the foundation for its follow-up collaboration with the PI, and ultimately help improve the healthcare of millions of patients living with IVD diseases.

下背痛（LBP）是下背部的疲劳，不适或疼痛，导致加拿大每年120亿美元的医疗支出。临床证据表明LBP与椎间盘（IVD）退变有关，由于原生IVD缺乏愈合能力，因此通常需要手术干预。目前正在开发多种用于IVD修复的植入式生物材料。然而，由于缺乏能够在实验室环境中重现体内条件的IVD生物反应器，该开发长期受到阻碍。本项目的重点是设计、制造和验证用于IVD研究的新型生物反应器。这种装置被设计成同时将压缩、弯曲和扭转载荷的能力联合收割机组合，同时与离体的整个器官培养完全相容。该项目将直接解决一家加拿大公司开发和验证用于IVD修复的水凝胶植入物的关键需求。该设备可以实现IVD植入物的高通量安全性和有效性评估，并减少冗长和昂贵的动物实验的需要。该项目将满足公司的需求，为其与PI的后续合作奠定基础，并最终帮助改善数百万IVD患者的医疗保健。